The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

In this video, Jonathan A. Bernstein, MD, discusses an American College of Allergy, Asthma & Immunology Annual Scientific ...

In this video, Gailen D. Marshall Jr., MD, PhD, chair of allergy and immunology at University of Mississippi Medical Center, discusses the clinical development of the nanobody compound lunsekimig for ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

The MHRA has approved depemokimab as an add on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

(Alliance News) - GSK PLC on Monday said Exdensur has been approved in the UK, for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...

Maryland lawmakers introduce the Affordable Inhalers and Nebulizers Act to reduce the cost of inhalers and expand Medicare ...

Teddy Roosevelt, 26th U.S. President and namesake of the teddy bear, was known for his vigor. Did a gallon of coffee consumed ...

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...